Track Bristol-Myers Squibb Company — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Bristol-Myers Squibb Company BMY · Stock Open Bristol-Myers Squibb Company in new tab

63.43 USD
Add to portfolio
P/E
14.72
EPS
4.54
Yield
3.76%
Safety Score
77
P/B
6.12
ROE
46.60
Beta
0.23
Target Price
66.21 USD
Bristol-Myers Squibb Company logo

Bristol-Myers Squibb Company

🧾 Earnings Recap – Q2 2026

Shares rose 3.5% following Q2 results that showed solid sales growth from the company’s growth portfolio and an upward revision to full-year revenue and adjusted EPS guidance, signaling investor approval of the company’s execution and pipeline progress.

  • Growth portfolio sales increased 14%, driven by 10 products attaining double-digit growth, including Reblozyl, Breyanzi, Camzyos, Opdualag, and Qvantig.
  • Full-year 2026 revenue and adjusted EPS guidance were raised, reflecting confidence in ongoing commercial momentum.
  • Key late-stage pipeline highlights include positive Phase III data for MeziKd in multiple myeloma, encouraging results from ADC programs in solid tumors, and ongoing development of multiple pivotal-readout assets.
  • Timing update on milvexian’s atrial fibrillation study pushed to Q1 2027 due to slower event accrual; Alzheimer’s psychosis program readouts expected in 2027 as well.
  • The company is preparing for the August 17 PDUFA date for iberdomide, which may launch as the first CELMoD commercial product.
📅
1M 6M YTD 1Y 2Y 5Y Max
Loading chart...
Key Metrics
Earnings dateOct. 29, 2026
P/E14.72
EPS4.54
Book Value10.93
Price to Book6.12
Debt/Equity201.86
% Insiders0.098%
Growth
Revenue Growth0.06%
Earnings Growth1.53%
Estimates
Forward P/E10.19
Forward EPS6.56
Target Mean Price66.21
Dividend
Dividend Yield3.76%
Annual dividends2.51 USD
Ex-Div. DateJuly 2, 2026
Payout54.89%
5y avg Yield3.55%

DCF Valuation

Tweak assumptions to recompute fair value for Bristol-Myers Squibb Company (BMY)
Currency: USD
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result
Fair Value (DCF)
—
Current Price
—
Upside
—
WACC
—
Terminal PV
—
Σ PV of FCFs
—
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

Bristol-Myers Squibb Company Logo Bristol-Myers Squibb Company Analysis (BMY)

United States Health Care Official Website Stock

Is Bristol-Myers Squibb Company a good investment? Bristol-Myers Squibb Company (BMY) is currently trading at 63.43 USD. Market analysts have a consensus price target of 66.21 USD. This suggests a potential upside from current levels.

In terms of valuation, the stock trades at a P/E ratio of 14.72. This relatively low multiple may signal that Bristol-Myers Squibb Company is undervalued compared to historical market norms.

Earnings Schedule: Bristol-Myers Squibb Company is expected to release its next earnings report on Oct. 29, 2026. The market consensus estimate for Forward EPS is 6.56.

For income investors, Bristol-Myers Squibb Company pays a dividend yield of 3.76%. With a payout ratio of 55%, the dividend appears sustainable.

Investor FAQ

Does Bristol-Myers Squibb Company pay a dividend?

Yes, it pays an annual dividend of 2.51 USD (3.76% yield).

What asset class is Bristol-Myers Squibb Company?

Bristol-Myers Squibb Company is classified as a Stock. You can compare it against 3 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be Oct. 29, 2026. The company currently has a trailing EPS of 4.54.

Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Opdualag to treat unresectable or metastatic melanoma; and Camzyos for the treatment of symptomatic obstructive HCM. The company also offers Zeposia to treat relapsing forms of multiple sclerosis; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Sotyktu to treat moderate-to-severe plaque psoriasis; Krazati for the treatment of KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); and Cobenfy to treat schizophrenia. In addition, it offers Eliquis for the reduction of risk of stroke/systemic embolism and for the treatment of DVT/PE; Revlimid, an oral immunomodulatory drug for multiple myeloma; Pomalyst/Imnovid for multiple myeloma; Sprycel for Philadelphia chromosome-positive chronic myeloid leukemia; and Abraxane to treat breast cancer. Further, the company provides Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC, as well as NSCLC and pancreatic cancer. It sells its products to wholesalers, distributors, specialty pharmacies, retailers, hospitals, clinics, and government agencies. The company has a strategic collaboration with Arcus Biosciences, Inc. to develop a treatment regimen that delivers tumor control in kidney cancer. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in Princeton, New Jersey.

Exchange Ticker
GER (Germany) BRM.DE
NYQ (United States) BMY
FRA (Germany) BRM.F
Trades
Dividend Yield
3.76%
5y avg 3.55%
Annual Dividends
2.51USD
Next Ex. Div Date
July 2, 2026
Payout Ratio
54.89%
Dividend History paid per year (USD)
Historical Dividends
Year Total Dividends
▸2027
2.03 USD
Aug. 2, 2027 (estimated) 0.6771
May 3, 2027 (estimated) 0.6771
Feb. 1, 2027 (estimated) 0.6771
▸2026
2.56 USD
Nov. 2, 2026 (estimated) 0.6664
Aug. 3, 2026 0.6300
May 1, 2026 0.6300
Feb. 2, 2026 0.6300
▸2025
2.48 USD
Nov. 3, 2025 0.6200
Aug. 1, 2025 0.6200
May 1, 2025 0.6200
Feb. 3, 2025 0.6200
▸2024
2.90 USD
Nov. 1, 2024 0.6000
Aug. 1, 2024 0.6000
June 3, 2024 0.5000
May 1, 2024 0.6000
Feb. 1, 2024 0.6000
▸2023
2.28 USD
Nov. 1, 2023 0.5700
Aug. 1, 2023 0.5700
May 1, 2023 0.5700
Feb. 1, 2023 0.5700
▸2022
2.16 USD
Nov. 1, 2022 0.5400
Aug. 1, 2022 0.5400
May 2, 2022 0.5400
Feb. 1, 2022 0.5400
▸2021
1.96 USD
Nov. 1, 2021 0.4900
Aug. 2, 2021 0.4900
May 3, 2021 0.4900
Feb. 1, 2021 0.4900
▸2020
1.80 USD
Nov. 2, 2020 0.4500
Aug. 3, 2020 0.4500
May 1, 2020 0.4500
Feb. 3, 2020 0.4500
▸2019
1.64 USD
Nov. 1, 2019 0.4100
Aug. 1, 2019 0.4100
May 1, 2019 0.4100
Feb. 1, 2019 0.4100
▸2018
1.60 USD
Nov. 1, 2018 0.4000
Aug. 1, 2018 0.4000
May 1, 2018 0.4000
Feb. 1, 2018 0.4000
▸2017
1.56 USD
Nov. 1, 2017 0.3900
Aug. 1, 2017 0.3900
May 1, 2017 0.3900
Feb. 1, 2017 0.3900
▸2016
1.52 USD
Nov. 1, 2016 0.3800
Aug. 1, 2016 0.3800
May 2, 2016 0.3800
Feb. 1, 2016 0.3800
▸2015
1.48 USD
Nov. 2, 2015 0.3700
Aug. 3, 2015 0.3700
May 1, 2015 0.3700
Feb. 2, 2015 0.3700
▸2014
1.44 USD
Nov. 3, 2014 0.3600
Aug. 1, 2014 0.3600
May 1, 2014 0.3600
Feb. 3, 2014 0.3600
▸2013
1.40 USD
Nov. 1, 2013 0.3500
Aug. 1, 2013 0.3500
May 1, 2013 0.3500
Feb. 1, 2013 0.3500
▸2012
1.36 USD
Nov. 1, 2012 0.3400
Aug. 1, 2012 0.3400
May 1, 2012 0.3400
Feb. 1, 2012 0.3400
▸2011
1.32 USD
Nov. 1, 2011 0.3300
Aug. 1, 2011 0.3300
May 2, 2011 0.3300
Feb. 1, 2011 0.3300
▸2010
1.28 USD
Nov. 1, 2010 0.3200
Aug. 2, 2010 0.3200
May 3, 2010 0.3200
Feb. 1, 2010 0.3200
▸2009
1.24 USD
Nov. 2, 2009 0.3100
Aug. 3, 2009 0.3100
May 1, 2009 0.3100
Feb. 2, 2009 0.3100
▸2008
1.24 USD
Nov. 3, 2008 0.3100
Aug. 1, 2008 0.3100
May 1, 2008 0.3100
Feb. 1, 2008 0.3100
▸2007
1.12 USD
Nov. 1, 2007 0.2800
Aug. 1, 2007 0.2800
May 1, 2007 0.2800
Feb. 1, 2007 0.2800
▸2006
1.12 USD
Nov. 1, 2006 0.2800
Aug. 1, 2006 0.2800
May 1, 2006 0.2800
Feb. 1, 2006 0.2800
▸2005
1.12 USD
Nov. 1, 2005 0.2800
Aug. 1, 2005 0.2800
May 2, 2005 0.2800
Feb. 1, 2005 0.2800
▸2004
1.12 USD
Nov. 1, 2004 0.2800
Aug. 2, 2004 0.2800
May 3, 2004 0.2800
Feb. 2, 2004 0.2800
▸2003
1.12 USD
Nov. 3, 2003 0.2800
Aug. 1, 2003 0.2800
May 1, 2003 0.2800
Feb. 1, 2003 0.2800
▸2002
1.12 USD
Nov. 1, 2002 0.2800
Aug. 1, 2002 0.2800
May 1, 2002 0.2800
Feb. 1, 2002 0.2800
▸2001
1.10 USD
Nov. 1, 2001 0.2750
Aug. 1, 2001 0.2750
May 1, 2001 0.2750
Feb. 1, 2001 0.2750
▸2000
0.98 USD
Nov. 1, 2000 0.2450
Aug. 1, 2000 0.2450
May 1, 2000 0.2450
Feb. 1, 2000 0.2450
▸1999
1.08 USD
Nov. 1, 1999 0.2150
Aug. 1, 1999 0.2150
May 1, 1999 0.2150
Feb. 1, 1999 0.4300
▸1998
1.56 USD
Nov. 1, 1998 0.3900
Aug. 1, 1998 0.3900
May 1, 1998 0.3900
Feb. 1, 1998 0.3900
▸1997
1.90 USD
Nov. 1, 1997 0.3800
Aug. 1, 1997 0.3800
May 1, 1997 0.3800
Feb. 1, 1997 0.7600
▸1996
3.00 USD
Nov. 1, 1996 0.7500
Aug. 1, 1996 0.7500
May 1, 1996 0.7500
Feb. 1, 1996 0.7500
▸1995
2.96 USD
Nov. 1, 1995 0.7400
Aug. 1, 1995 0.7400
May 1, 1995 0.7400
Feb. 1, 1995 0.7400
▸1994
2.92 USD
Nov. 1, 1994 0.7300
Aug. 1, 1994 0.7300
May 1, 1994 0.7300
Feb. 1, 1994 0.7300
▸1993
2.88 USD
Nov. 1, 1993 0.7200
Aug. 1, 1993 0.7200
May 1, 1993 0.7200
Feb. 1, 1993 0.7200
▸1992
2.76 USD
Nov. 1, 1992 0.6900
Aug. 1, 1992 0.6900
May 1, 1992 0.6900
Feb. 1, 1992 0.6900
▸1991
2.40 USD
Nov. 1, 1991 0.6000
Aug. 1, 1991 0.6000
May 1, 1991 0.6000
Feb. 1, 1991 0.6000
▸1990
2.12 USD
Nov. 1, 1990 0.5300
Aug. 1, 1990 0.5300
May 1, 1990 0.5300
Feb. 1, 1990 0.5300
▸1989
2.00 USD
Nov. 1, 1989 0.5000
Aug. 1, 1989 0.5000
May 1, 1989 0.5000
Feb. 1, 1989 0.5000
▸1988
1.68 USD
Nov. 1, 1988 0.4200
Aug. 1, 1988 0.4200
May 1, 1988 0.4200
Feb. 1, 1988 0.4200
▸1987
2.10 USD
Nov. 1, 1987 0.3500
Aug. 1, 1987 0.3500
May 1, 1987 0.7000
Feb. 1, 1987 0.7000
▸1986
1.17 USD
Sept. 29, 1986 0.5500
June 27, 1986 0.5500
March 31, 1986 0.0688
▸1985
1.88 USD
Dec. 27, 1985 0.4700
Sept. 30, 1985 0.4700
June 28, 1985 0.4700
March 29, 1985 0.4700
▸1984
1.60 USD
Dec. 28, 1984 0.4000
Oct. 1, 1984 0.4000
June 29, 1984 0.4000
April 2, 1984 0.4000
▸1983
2.03 USD
Dec. 30, 1983 0.3000
Oct. 3, 1983 0.3000
July 1, 1983 0.3000
April 4, 1983 0.6000
Jan. 3, 1983 0.5250
▸1982
2.04 USD
Oct. 4, 1982 0.5250
July 2, 1982 0.5250
April 2, 1982 0.5250
Jan. 4, 1982 0.4600
▸1981
1.78 USD
Oct. 5, 1981 0.4600
July 6, 1981 0.4600
May 1, 1981 0.4000
April 6, 1981 0.4600
▸1980
1.20 USD
Oct. 6, 1980 0.4000
June 30, 1980 0.4000
March 28, 1980 0.4000
▸1979
1.44 USD
Dec. 28, 1979 0.3600
Oct. 5, 1979 0.3600
June 29, 1979 0.3600
April 2, 1979 0.3600
▸1978
1.22 USD
Dec. 29, 1978 0.3050
Oct. 2, 1978 0.3050
June 30, 1978 0.3050
March 31, 1978 0.3050
▸1977
1.38 USD
Dec. 30, 1977 0.2750
Oct. 3, 1977 0.2750
June 27, 1977 0.2750
March 30, 1977 0.5500
▸1976
1.80 USD
Dec. 29, 1976 0.4500
Sept. 28, 1976 0.4500
June 28, 1976 0.4500
March 29, 1976 0.4500
▸1975
1.65 USD
Dec. 26, 1975 0.4500
Sept. 29, 1975 0.4000
June 27, 1975 0.4000
March 31, 1975 0.4000
▸1974
1.52 USD
Dec. 27, 1974 0.3800
Sept. 30, 1974 0.3800
June 28, 1974 0.3800
March 28, 1974 0.3800
▸1973
1.62 USD
Dec. 28, 1973 0.3300
Oct. 1, 1973 0.3300
July 30, 1973 0.3300
April 30, 1973 0.3300
Jan. 29, 1973 0.3000
▸1972
0.60 USD
Oct. 31, 1972 0.3000
July 26, 1972 0.3000
Upcoming Dividends
Name Payment Date Status Amount
Bristol-Myers Squibb Company Aug 03, 2026 0.63 USD
Bristol-Myers Squibb Company May 01, 2026 0.63 USD
Bristol-Myers Squibb Company Feb 02, 2026 0.63 USD
Bristol-Myers Squibb Company Nov 03, 2025 0.62 USD
Stock Splits
Split Date Split Ratio to 1
May 31, 1977 2:1
May 27, 1983 2:1
June 10, 1987 2:1
March 3, 1997 2:1
March 1, 1999 2:1
Aug. 7, 2001 1.05067
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion